
               
               
               12 CLINICAL PHARMACOLOGY
               
               
                  
                     
                     
                     12.1 Mechanism of Action
                     
                        The mechanism by which niacin alters lipid profiles has not been well defined.  It may involve several actions including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity, which may increase the rate of chylomicron triglyceride removal from plasma.  Niacin decreases the rate of hepatic synthesis of VLDL and LDL, and does not appear to affect fecal excretion of fats, sterols, or bile acids.
                     
                     
                  
               
               
                  
                     
                     
                     12.2 Pharmacodynamics
                     
                        Niacin functions in the body after conversion to nicotinamide adenine dinucleotide (NAD) in the NAD coenzyme system. Niacin (but not nicotinamide) in gram doses reduces total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), and triglycerides (TG), and increases high-density lipoprotein cholesterol (HDL-C). The magnitude of individual lipid and lipoprotein responses may be influenced by the severity and type of underlying lipid abnormality. The increase in HDL-C is associated with an increase in apolipoprotein A-I (Apo A-I) and a shift in the distribution of HDL subfractions. These shifts include an increase in the HDL2:HDL3 ratio, and an elevation in lipoprotein A-I (Lp A-I, an HDL-C particle containing only Apo A-I). Niacin treatment also decreases serum levels of apolipoprotein B-100 (Apo B), the major protein component of the very low-density lipoprotein (VLDL) and LDL fractions, and of Lp(a), a variant form of LDL independently associated with coronary risk. In addition, preliminary reports suggest that niacin causes favorable LDL particle size transformations, although the clinical relevance of this effect requires further investigation.  The effect of niacin-induced changes in lipids/proteins on cardiovascular morbidity or mortality in individuals without preexisting coronary disease has not been established.
                        A variety of clinical studies have demonstrated that elevated levels of TC, LDL-C, and Apo B promote human atherosclerosis. Similarly, decreased levels of HDL-C are associated with the development of atherosclerosis. Epidemiological investigations have established that cardiovascular morbidity and mortality vary directly with the level of Total-C and LDL-C, and inversely with the level of HDL-C.
                        Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoprotein (IDL), and their remnants, can also promote atherosclerosis. Elevated plasma TG are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease (CHD). As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.
                     
                     
                  
               
               
                  
                     
                     
                     12.3 Pharmacokinetics
                     
                        
                           Absorption
                        
                        Due to extensive and saturable first-pass metabolism, niacin concentrations in the general circulation are dose dependent and highly variable.  Time to reach the maximum niacin plasma concentrations was about 5 hours following NIASPAN. To reduce the risk of gastrointestinal (GI) upset, administration of NIASPAN with a low-fat meal or snack is recommended.
                        Single-dose bioavailability studies have demonstrated that the 500 mg and 1000 mg tablet strengths are dosage form equivalent but the 500 mg and 750 mg tablet strengths are not dosage form equivalent.
                        
                           Metabolism
                        
                        The pharmacokinetic profile of niacin is complicated due to extensive first-pass metabolism that is dose-rate specific and, at the doses used to treat dyslipidemia, saturable. In humans, one pathway is through a simple conjugation step with glycine to form nicotinuric acid (NUA). NUA is then excreted in the urine, although there may be a small amount of reversible metabolism back to niacin.  The other pathway results in the formation of nicotinamide adenine dinucleotide (NAD). It is unclear whether nicotinamide is formed as a precursor to, or following the synthesis of, NAD. Nicotinamide is further metabolized to at least N-methylnicotinamide (MNA) and nicotinamide-N-oxide (NNO).  MNA is further metabolized to two other compounds, N-methyl-2-pyridone-5-carboxamide (2PY) and N-methyl-4-pyridone-5-carboxamide (4PY). The formation of 2PY appears to predominate over 4PY in humans.  At the doses used to treat hyperlipidemia, these metabolic pathways are saturable, which explains the nonlinear relationship between niacin dose and plasma concentrations following multiple-dose NIASPAN administration.
                        Nicotinamide does not have hypolipidemic activity; the activity of the other metabolites is unknown.
                        
                           Elimination
                        
                        Following single and multiple doses, approximately 60 to 76% of the niacin dose administered as NIASPAN was recovered in urine as niacin and metabolites; up to 12% was recovered as unchanged niacin after multiple dosing.  The ratio of metabolites recovered in the urine was dependent on the dose administered.
                        
                           Pediatric Use
                        
                        No pharmacokinetic studies have been performed in this population (â‰¤16 years) [see Use in Specific Populations (8.4)]. 
                        
                           Geriatric Use
                        
                        No pharmacokinetic studies have been performed in this population (> 65 years) [see Use in Specific Populations (8.5)].
                        
                           Renal Impairment
                        
                        No pharmacokinetic studies have been performed in this population.  NIASPAN should be used with caution in patients with renal disease [see Warnings and Precautions (5)].
                        
                           Hepatic Impairment
                        
                        No pharmacokinetic studies have been performed in this population.  Active liver disease, unexplained transaminase elevations and significant or unexplained hepatic dysfunction are contraindications to the use of NIASPAN [see Contraindications (4) and Warnings and Precautions (5.3)].
                        
                           Gender
                        
                        Steady-state plasma concentrations of niacin and metabolites after administration of NIASPAN are generally higher in women than in men, with the magnitude of the difference varying with dose and metabolite.  This gender differences observed in plasma levels of niacin and its metabolites may be due to gender-specific differences in metabolic rate or volume of distribution.  Recovery of niacin and metabolites in urine, however, is generally similar for men and women, indicating that absorption is similar for both genders [see Gender (8.8)].
                        
                           Drug interactions
                        
                        
                           Fluvastatin
                        
                        Niacin did not affect fluvastatin pharmacokinetics [see Drug Interactions (7.1)].
                        
                           Lovastatin
                        
                        When NIASPAN 2000 mg and lovastatin 40 mg were co-administered, NIASPAN increased lovastatin Cmax and AUC by 2% and 14%, respectively, and decreased lovastatin acid Cmax and AUC by 22% and 2%, respectively.  Lovastatin reduced NIASPAN bioavailability by 2-3% [see Drug Interactions (7.1)].
                        
                           Simvastatin
                        
                        When NIASPAN 2000 mg and simvastatin 40 mg were co-administered, NIASPAN increased simvastatin Cmax and AUC by 1% and 9%, respectively, and simvastatin acid Cmax and AUC by 2% and 18%, respectively.  Simvastatin reduced NIASPAN bioavailability by 2% [see Drug Interactions (7.1)].
                        
                           Bile Acid Sequestrants
                        
                        An in vitro study was carried out investigating the niacin-binding capacity of colestipol and cholestyramine.  About 98% of available niacin was bound to colestipol, with 10 to 30% binding to cholestyramine [see Drug Interactions (7.2)].
                     
                     
                  
               
            
         